Description
HS-20089 is an investigational medication currently being studied in clinical trials. It is being evaluated as part of a combination therapy for advanced solid tumors, including colorectal cancer, in Phase 1 trials. These early-phase trials focus primarily on determining the safety and appropriate dosage of HS-20089 when used alongside other cancer treatments like platinum-based chemotherapy or bevacizumab. The trials are open-label, meaning that both the researchers and the participants know which treatments are being given. The goal is to find the maximum dose that can be tolerated (MTD) or the maximum applicable dose (MAD) and to get initial information about how well the combination works. HS-20089 is being studied in combination with other drugs like HS-10502, platinum agents, and bevacizumab.
Mechanism of Action
HS-20089 is being investigated in combination with other anticancer agents. The specific way HS-20089 works (its mechanism of action) is not fully defined in the available trial information. It is being studied alongside various other drugs, suggesting it may target different pathways or mechanisms involved in tumor growth or resistance to other therapies. Further research is needed to understand its precise molecular target or function.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.